Title:
MST1 KINASE INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/073906
Kind Code:
A1
Abstract:
Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutation thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.
Inventors:
LIU QINGSONG (CN)
LIU JING (CN)
WU YUN (CN)
WANG WENLIANG (CN)
WANG BEILEI (CN)
QI ZIPING (CN)
WANG JUNJIE (CN)
WANG WENCHAO (CN)
QI SHUANG (CN)
WANG LI (CN)
LIU JING (CN)
WU YUN (CN)
WANG WENLIANG (CN)
WANG BEILEI (CN)
QI ZIPING (CN)
WANG JUNJIE (CN)
WANG WENCHAO (CN)
QI SHUANG (CN)
WANG LI (CN)
Application Number:
PCT/CN2019/110048
Publication Date:
April 16, 2020
Filing Date:
October 09, 2019
Export Citation:
Assignee:
HEFEI INST PHYSICAL SCI CAS (CN)
International Classes:
C07D475/00; A61K31/519; A61P1/16; A61P3/10
Domestic Patent References:
| WO2008050096A1 | 2008-05-02 | |||
| WO2014145909A2 | 2014-09-18 |
Foreign References:
| CN105801582A | 2016-07-27 | |||
| CN107151250A | 2017-09-12 | |||
| CN201280011749A | 2012-03-02 |
Other References:
ARDESTANI A ET AL.: "MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes", NAT MED, vol. 20, 2014, pages 385 - 397, XP055132760, DOI: 10.1038/nm.3482
FAN F ET AL.: "Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration", SCI. TRANSL. MED., vol. 8, 2016, pages 352ra108
ANAND R ET AL.: "Toward the Development of a Potent and Selective Organoruthenium Mammalian Sterile 20 Kinase Inhibitor", J. MED. CHEM., vol. 52, 2009, pages 1602 - 1611, XP055139702, DOI: 10.1021/jm8005806
"The Pharmacological Basis of Therapeutics", 1996, MCGRAW-HILL
DAVISBREWSTER, NAT. REV. DRUG DISC., vol. 3, 2004, pages 1023 - 1034
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
See also references of EP 3868762A4
FAN F ET AL.: "Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration", SCI. TRANSL. MED., vol. 8, 2016, pages 352ra108
ANAND R ET AL.: "Toward the Development of a Potent and Selective Organoruthenium Mammalian Sterile 20 Kinase Inhibitor", J. MED. CHEM., vol. 52, 2009, pages 1602 - 1611, XP055139702, DOI: 10.1021/jm8005806
"The Pharmacological Basis of Therapeutics", 1996, MCGRAW-HILL
DAVISBREWSTER, NAT. REV. DRUG DISC., vol. 3, 2004, pages 1023 - 1034
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
See also references of EP 3868762A4
Attorney, Agent or Firm:
SHANGCHENG & PARTNERS (CN)
Download PDF: